

01-27-06

*JTW*



Express Mail Label No. EV 734133946 US Dated: January 25, 2006

Docket No.: 0019240.00477US2  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Martha G. Welch et al.

Application No.: 10/799941

Confirmation No.: 8041

Filed: March 11, 2004

Art Unit: 1654

For: NOVEL MULTYPEPTIDE REGIMEN FOR THE  
TREATMENT OF AUTISTIC SPECTRUM,  
BEHAVIORAL, EMOTIONAL AND  
VISCERAL  
INFLAMMATION/AUTOIMMUNE  
DISORDERS

Examiner: J. I. Harle

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT (IDS)**

Dear Sir:

This Information Disclosure Statement is being filed prior to the mailing date of a first Office Action on the merits. No fee is required.

Applicants request that the Examiner initial and return a copy of the enclosed Form PTO SB-08 with the next communication.

Dated: January 25, 2006

Respectfully submitted,

By *Jane M. Love*

Jane M. Love, Ph.D.

Registration No.: 42,812

WILMER CUTLER PICKERING HALE AND  
DORR LLP

399 Park Avenue

New York, New York 10022

(212) 937-7233

Attorney for Applicants



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/799941-Conf. #8041
				Filing Date	March 11, 2004
				First Named Inventor	Martha G. Welch
				Art Unit	1654
				Examiner Name	J. I. Harle
Sheet	1	of	1	Attorney Docket Number	19240.477 US2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	Welch et al.: Neuropeptide Treatment of Genetic and Acquired IBD and Concomitant Brain Activation in Areas Abnormal in Autism, Autism Abstracts presented at Society for Neuroscience, November 8-12, 2003, New Orleans, LA, pg. 9	
	CB	Copy of International Search Report of International Application No. PCT/US2005/008277	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

5482331



Application No. (if known): 10/799941

Attorney Docket No.: 0019240.00477US2

## Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, No. EV 734133946 US in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on January 25, 2006  
Date

Signature

Jane M. Love, Ph.D.

Typed or printed name of person signing Certificate

42,812

Registration Number, if applicable

(212) 230-8800

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Information Disclosure Statement (1 page)  
Form PTO SB-08 (1 page)  
2 References (1 page)  
Return Receipt Postcard